CIK 0001677077 · <br>Emerging growth company
Alzamend Neuro, Inc.
Sign in to watch- Ticker
- ALZN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Apr 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811822909
- Phone
- 844-722-6333
- Business address
- 480 PEACHTREE ROAD NE, SECOND FLOOR, SUITE 103, ATLANTA, GA, 30326
- 10-K Report Annual Report
- 144/A Insider Sale of Securities
- 8-K Event Bylaws or fiscal year change
- 4 Open-market sale Director sold 1,224 shares at an average $5.06 ($6,196)
- 144 Insider Sale of Securities
- 8-K Event Bylaws or fiscal year change · Regulation FD disclosure
- 8-K Event Shareholder vote results
- 424B3 Offering Prospectus
- EFFECT Other Notice of Effectiveness
- CORRESP Other Correspondence Between Filers and SEC Staff
- S-1/A Offering Registration Statement
- 4 Open-market buy Director bought 3,334 shares at $0.99 ($3,285)
- 4 Open-market buy Director bought 2,905 shares at $1.02 ($2,969)
- 4 Open-market buy Chief Financial Officer bought 5,000 shares at $1.01 ($5,048)
- UPLOAD Other SEC-generated Letter
- 4 Open-market buy Director bought 5,000 shares at $0.98 ($4,892)
- DEFA14A Proxy Proxy Materials
- 4 Open-market buy Director bought 5,000 shares at $0.97 ($4,852)
- 4 Open-market buy Director bought 5,000 shares at $0.96 ($4,810)
- DEFA14A Proxy Proxy Materials
Page 4 of 20 · 398 filings